Coherus Oncology Inc (CHRS) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.78 is considered Undervalued compared with the five-year average of -7.78. The fair price of Coherus Oncology Inc (CHRS) is between 3.53 to 5.28 according to relative valuation method. Compared to the current price of 1.65 USD , Coherus Oncology Inc By Undervalued By 53.28%.

Relative Value

Fair Zone

3.53-5.28

Current Price：1.65

53.28%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Coherus Oncology Inc (CHRS) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Coherus Oncology Inc (CHRS) has a current Price-to-Book (P/B) ratio of 1.81. Compared to its 3-year average P/B ratio of -1.31, the current P/B ratio is approximately -238.07% higher. Relative to its 5-year average P/B ratio of 1.59, the current P/B ratio is about 13.83% higher. Coherus Oncology Inc (CHRS) has a Forward Free Cash Flow (FCF) yield of approximately -54.46%. Compared to its 3-year average FCF yield of -53.77%, the current FCF yield is approximately 1.29% lower. Relative to its 5-year average FCF yield of -34.52%, the current FCF yield is about 57.76% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for CHRS competitors is 13.79, providing a benchmark for relative valuation. Coherus Oncology Inc Corp (CHRS.O) exhibits a P/S ratio of 1.78, which is -87.12% above the industry average. Given its robust revenue growth of 91.19%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of CHRS increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of CHRS in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is CHRS currently overvalued or undervalued?

What is Coherus Oncology Inc (CHRS) fair value?

CHRS's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Coherus Oncology Inc (CHRS) is between 3.53 to 5.28 according to relative valuation method.

How does CHRS's valuation metrics compare to the industry average?

The average P/S ratio for CHRS's competitors is 13.79, providing a benchmark for relative valuation. Coherus Oncology Inc Corp (CHRS) exhibits a P/S ratio of 1.78, which is -87.12% above the industry average. Given its robust revenue growth of 91.19%, this premium appears sustainable.

What is the current P/B ratio for Coherus Oncology Inc (CHRS) as of Mar 03 2026?

As of Mar 03 2026, Coherus Oncology Inc (CHRS) has a P/B ratio of 1.81. This indicates that the market values CHRS at 1.81 times its book value.

What is the current FCF Yield for Coherus Oncology Inc (CHRS) as of Mar 03 2026?

As of Mar 03 2026, Coherus Oncology Inc (CHRS) has a FCF Yield of -54.46%. This means that for every dollar of Coherus Oncology Inc's market capitalization, the company generates -54.46 cents in free cash flow.

What is the current Forward P/E ratio for Coherus Oncology Inc (CHRS) as of Mar 03 2026?

As of Mar 03 2026, Coherus Oncology Inc (CHRS) has a Forward P/E ratio of -1.96. This means the market is willing to pay $-1.96 for every dollar of Coherus Oncology Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Coherus Oncology Inc (CHRS) as of Mar 03 2026?

As of Mar 03 2026, Coherus Oncology Inc (CHRS) has a Forward P/S ratio of 1.78. This means the market is valuing CHRS at $1.78 for every dollar of expected revenue over the next 12 months.

CHRS Valuation